氨酸通过mTORC1/LXRα介导的巨细胞重编程和rspo2/β-catenin轴抑制来减轻骨关节炎
Ke Zheng1,2, Jiebin Zhang2, Wenxiang Liu2
1Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cartilage
|November 7, 2025
概括
素 (Leu) 补充剂通过通过mTORC1/LXRα通路重编程巨细胞,有效治疗关节炎. 这种干预减少了软骨损伤和骨细胞的形成,为关节疾病提供了一种新的营养策略.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 整形外科 整形外科 整形外科
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,其特点是软骨分解和骨菌形成.
- 巨细胞两极分化在OA的发病过程中起着至关重要的作用.
- 正在探索营养干预措施,如氨基酸补充剂,用于OA治疗.
研究的目的:
- 阐明氨酸 (Leu) 改善原酶诱导性骨关节炎 (CIOA) 的分子机制.
- 研究Leu在调节巨细胞极化中的作用及其对Rspo2/β-catenin轴在chondroprogenitors中的影响.
- 建立一个新的"新陈代谢-免疫-软骨"轴,用于OA治疗.
主要方法:
- 建立一个CIOA小鼠模型,使用微型CT和本病理学分析.
- 管理Leu干预和治疗效果的评估.
- 使用LXRα抑制剂 (GSK2033) 进行集成的多组学分析,机械分析和功能验证.
主要成果:
- 的干预显著减少了软骨退化 (42%的OARSI得分下降) 和骨菌形成 (58%的体积减少).
- 莱乌激活了mTORC1/LXRα通路,促进了类似M2的巨细胞两极分化.
- 抑制了Rspo2和减弱了chondroprogenitors中的β-catenin信号,改善了软骨功能.
结论:
- 氨酸建立了"新陈代谢-免疫-软骨"轴,协调巨细胞重编程与RSpo2/β-catenin轴的抑制,以实现双重OA治疗潜力.
- 营养氨基酸在退行性关节疾病中充当免疫代谢调节剂.
- 补充剂是一种可行的策略,可以在创伤性关节炎中中断炎症和骨重塑.
更多相关视频
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
14.2K
12:23Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model
Published on: April 24, 2020
20.8K
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
